Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Advanced, Low Proliferative NEN G3
NCT04524208Phase 2Active, not recruiting
- Start
- Mar 2021
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of cabozantinib in neuroendocrine neoplasms (NENs). Started Mar 2021; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
neuroendocrine neoplasms (NENs)
Beyond the preview
Go deeper on NCT04524208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04524208.